Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Histogen Inc. | cnat-ex322_13.htm |
| EX-32.1 - EX-32.1 - Histogen Inc. | cnat-ex321_12.htm |
| EX-31.2 - EX-31.2 - Histogen Inc. | cnat-ex312_6.htm |
| EX-31.1 - EX-31.1 - Histogen Inc. | cnat-ex311_8.htm |
| 10-K - 10-K - Histogen Inc. | cnat-10k_20171231.htm |
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
(1) |
Registration Statement (Form S-8 No. 333-211162) pertaining to the Conatus Pharmaceuticals Inc. 2013 Incentive Award Plan, |
|
(2) |
Registration Statement (Form S-8 No. 333-190134) pertaining to the Conatus Pharmaceuticals Inc. 2013 Incentive Award Plan, the Conatus Pharmaceuticals Inc. 2006 Equity Incentive Award Plan and the Conatus Pharmaceuticals Inc. 2013 Employee Stock Purchase Plan, and |
|
(3) |
Registration Statement (Form S-3 No. 333-220014) of Conatus Pharmaceuticals Inc.; |
of our report dated March 8, 2018, with respect to the financial statements of Conatus Pharmaceuticals Inc. included in this Annual Report (Form 10-K) of Conatus Pharmaceuticals Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
San Diego, California
March 8, 2018